Tasmanian devil cancer genome mapped

NewsGuard 100/100 Score

Researchers, including those from Wellcome Trust Sanger Institute near Cambridge, have sequenced the genome of a facial cancer that is threatening the existence of the Tasmanian devil.

The team of researchers has worked to piece together the genome of a fatal cancer that is sweeping through Tasmanian devils. Their work gives important clues to how the tumor evades detection by the devils' immune system and shows - for the first time - that the devil in which the tumor originated was a female. The devil disease, which causes tumors to the head and face, is fatal, usually within six to nine months of the onset of symptoms.

Tasmanian devil facial tumor disease was first seen on the island of Tasmania in 1996 and has spread widely since. As a result, the Tasmanian devil is at risk of extinction, and is on the red list of the International Union for the Conservation of Nature and Natural Resources.

The cancer is a facial tumor and is one of only two naturally occurring transmissible cancers known (the other affects dogs). Transmissible cancers pass between animals by the physical transfer of cancer cells. Because the cancer is spread by the physical exchange of cancer cells, all tumors killing devils today are descended from the same single cancer, originating in a single devil.Tasmanian Devil

Thus the researchers termed the cancer genome “immortal devil” and sequenced the genomes of a healthy male and female devil and the genomes of tumors taken from two devils from the north and south of Tasmania. By comparing the cancer genomes with the normal genomes, they were able to work out which mutations arose as the cancer developed and which were normal genetic variants present in the genome of the original devil.

They found more than 17 000 genetic mutations in the cancer genome - fewer than expected. “Our findings indicate that it's a relatively stable cancer, one whose genome has remained fairly intact in spite of the fact that it's transmissible and it has passed through a number of individuals,” says Dr Elizabeth Murchison, lead author on the paper. “This shows that a cancer does not need to have an incredibly unstable genome in order to become transmissible.”

Team leader Dr Janine Deakin of the Research School of Biology at the Australian National University said on Friday the devil tumor had changed very little over the last 16 years. “That's really unusual for cancers, because usually for human cancers evolution is rapid and the tumor will be completely different between the original tumor and its metastases,” Dr Deakin said in a statement. “In this work we confirmed that the devil tumor is genetically very stable.”

“In humans, you are usually working with a rapidly evolving cancer and it's hard to identify the important things because it's all happening so fast,” Dr Deakin said. “The devil is going to be a good model for looking at some human cancers because it is so stable - with everything happening slower we have a better chance of finding those things out.”

The researchers identified 458 genes with mutations that change the coding regions (the parts that contain the instructions to make proteins), including mutations in two genes that are frequently mutated in human cancers. The researchers are now planning to build on this work and explore further how this cancer evades detection by the devil immune system.

“We still don't know how the cancer is able to spread without eliciting an immune response,” says Elizabeth. “We'd like to understand this more, ultimately so that we can work to develop vaccines and therapies that could help with conservation.”

“Cancers that transmit through populations are obviously incredibly rare, but we should use the Tasmanian devil example to understand the process to be prepared in the extremely unlikely event that such an epidemic ever occurs in humans,” says Professor Mike Stratton, senior author and Director of the Wellcome Trust Sanger Institute.

“Having the genome should also allow us to identify cancer-causing genes, and hopefully find drugs that may help to control the disease,” says Katherine Belov, an authority on Tasmanian devils at the University of Sydney, who was not involved in the study. “There is some early evidence that the disease is behaving differently in devils in north-west Tasmanian populations,” says Belov. “The disease there is affecting fewer devils and taking longer to kill them off, and at this stage we don't know whether that's because the devils there are more resistant, or the tumor strains are different, or both,” she says. “Genomics will help us to solve this.”

The research was published in the scientific journal PLoS Genetics.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Tasmanian devil cancer genome mapped. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/news/20120221/Tasmanian-devil-cancer-genome-mapped.aspx.

  • MLA

    Mandal, Ananya. "Tasmanian devil cancer genome mapped". News-Medical. 19 April 2024. <https://www.news-medical.net/news/20120221/Tasmanian-devil-cancer-genome-mapped.aspx>.

  • Chicago

    Mandal, Ananya. "Tasmanian devil cancer genome mapped". News-Medical. https://www.news-medical.net/news/20120221/Tasmanian-devil-cancer-genome-mapped.aspx. (accessed April 19, 2024).

  • Harvard

    Mandal, Ananya. 2018. Tasmanian devil cancer genome mapped. News-Medical, viewed 19 April 2024, https://www.news-medical.net/news/20120221/Tasmanian-devil-cancer-genome-mapped.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment